News about "Muscle-Invasive Bladder Cancer "

FDA Grants Priority Review to Astellas and Pfizer's Bladder Cancer Combination Therapy

FDA Grants Priority Review to Astellas and Pfizer's Bladder Cancer Combination Therapy

Astellas and Pfizer’s Padcev-Keytruda combination moves closer to expanded approval, offering a potential new treatment option to reduce recurrence and improve survival in bladder cancer patients.

Muscle-invasive Bladder Cancer | 21/04/2026 | By News Bureau

KEYTRUDA Plus Padcev Improves Survival Outcomes in MIBC

KEYTRUDA Plus Padcev Improves Survival Outcomes in MIBC

KEYTRUDA plus Padcev significantly improved survival and pathologic complete response rates in cisplatin-eligible patients with muscle-invasive bladder cancer when used before and after surgery.

Muscle-Invasive Bladder Cancer | 18/12/2025 | By News Bureau 109


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members